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Dear Editor, 
Neuroacanthocytosis (NA) is a heterogeneous group of inherited diseases in which progressive 
neurological syndromes coincide with occasional laboratory findings of red blood cell 
acanthocytosis[1]. Elevated creatine kinase (CK) and serum transaminases may also be found [1]. 
Chorea-acanthocytosis (ChAc) is a very rare autosomal recessive NA associated with mutations in 
the VPS13A gene that encodes chorein protein [2, 3]. ChAc symptoms include chorea, parkinsonism 
Journal Pre-proof
Jo
ur
na
l P
re
-p
ro
of
and the orolinguofacial dyskinesia characteristic of the disease [1]. ChAc is also associated with a 
subcortical type of cognitive impairment, psychiatric symptoms and epileptic seizures [1, 4-6]. The 
symptoms may also include myopathy and axonal neuropathy [1, 7]. Neuropathological atrophy, 
especially in the caudate, putamen and pallidum may also occur [4, 8]. 
A 40-year old immigrant man born in the Middle East was referred to the neurological department 
of Helsinki University Hospital because of severe dystonia causing problems with speech and 
walking. The patient had changes resembling aphtha in his mouth and an itchy rash in his lower 
extremities and trunk. He had first noticed these symptoms in his early thirties, and they had 
progressively aggravated. 
The patient’s older brother living in his homeland had similar neurological and dermatological 
symptoms. The brother’s symptoms had begun when he was in his twenties, and due to the gradual 
progression of the disease he had eventually become wheelchair bound. The parents were not 
known to be consanguineous. They had been neurologically healthy, although the mother had had 
an itchy rash. 
In the neurological examination, the patient had dysarthria, orofacial dystonia, and dystonia of the 
head, throat and extremities. His mouth repeatedly shut abruptly and his jaws and teeth involuntary 
hit each other, making a clicking sound. He almost constantly smacked and made sucking 
movements with his lips due to substantial saliva excretion. All cranial nerve functions were intact. 
Choreoathetosis was present in all his extremities and in upper body. The finger-to-nose and heel-
to-knee tests showed dysmetria and ataxia on both sides. The fine motor skills of his hands were 
impaired and his vibratory sensation was reduced in the left and lacking in the right lower 
extremity. Tendon reflexes were missing from all other extremities except the right upper extremity. 
The patient did not use any mobility aids, but he swayed in all directions while walking and dragged 
his right leg. His balance was unstable even in a sitting position. 
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The patient had several small ulcerations in his gums resembling aphthae and severe scars on his 
lower lip. Biopsies revealed actinic cheilitis, fibrosis and atypical keratinocytes. He had a purple 
coin-shape rash in his malleoli, knees, lower back, and left upper inguinal area. Histological 
analysis showed chronic eczema. 
The neuropsychological examination was performed using modified Motor-Free Visual Perception 
Test (MVPT), Wechsler Adult Intelligence Scale III (WAIS-III), Wechsler Memory Scale Revised 
and third edition (WMS-R and WMS-III), Benton visual retention test C (Benton-C), Rivermead 
Behavioural Memory Test (RBMT-D) and Trail Making Test A (TMT-A), taking into account the 
limitations caused by the patient’s symptoms. It revealed attention problems and difficulties 
concentrating on assignments and memorizing, but pivotal issues were recalled later and there was 
no abnormal forgetfulness. His ability to estimate time, dates and prizes was intact. Tests of 
calculation at basic level were normal. At the time of the examination, noticeable psychiatric 
symptoms were absent. 
His cerebral CT was normal and an MRI (3T) revealed no atrophy or intensity changes of caudate 
or other areas of the basal ganglia. The only finding was very mild atrophy of vermis. EMG showed 
multiple slight abnormalities, suggesting neuropathy of several peripheral nerves, but the findings 
did not fulfil the criteria of polyneuropathy. An electrocardiogram (ECG) showed sinus rhythm with 
signs of left ventricular hypertrophy. An echocardiogram revealed possible slight hypokinesia in the 
basal septum. 
The morphology of erythrocytes was analysed in a blood smear test twice, but only a few spiked 
acanthocytes and burr cells were observed. Because of their scarcity, the laboratory specialist did 
not consider them diagnostic for acanthocytosis. CK was elevated in all seven tests. The medium 
CK value was 1027 U/l (range 426–1917U/l). Cholesterol values were spontaneously quite low, 
total cholesterol was 3.1 mmol/l, LDL was 1.8mmol/l, HDL was 0.76mmol/l and triglyceride was 
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1.04 mmol/l. Vitamin A and vitamin E were within normal limits, but the level of vitamin D (D25) 
was below 10 (normal range > 50nmol/l). After three weeks of substitution with 100microg/day the 
vitamin D level had risen to 41nmol/l. Hypoalphalipoproteinemia was observed, the LipoA value 
was 0.87g/l (normal limit > 1.2g/l), LipoB was 0.77g/l (normal limit < 0.9g/l) and the serum 
ApoB/ApoA1 ratio was elevated at 0.88 (normal limit < 0.75). The genetic tests for Huntington’s 
disease and the HLA B*51 factor associated with Behcet's disease were negative. The results of 
tests for Wilson Disease, celiac disease, folate and vitamin B12 were within normal limits. CSF 
protein level and cell count were normal. Acute and subacute central nervous system infections 
(HIV, syphilis, Lyme neuroborreliosis, sarcoidosis, tick-borne encephalitis) were excluded. 
Genetic analysis for ChAC was performed in a diagnostic genetic laboratory in Germany. Two 
novel heterozygous deletion mutations in the VPS13A gene were found: c.8148delT 
(p.Phe2719Leufs*5) and c.5899delA (p.Arg1967Aspfs*18) (Ref seq. NM_033305.2). As both 
mutations are believed to lead to a frameshift and premature stop codon, resulting in a truncated 
chorein protein, they are considered likely to be pathogenic. Neither mutation has been reported in 
the GnomAD database (http://gnomad.broadinstitute.org/, accessed 08/2019). 
Later, the patient had several epileptic tonic-clonic seizures. His EEG showed post-ictal diffuse 
slowing, but epileptiform findings were no longer present. Valproic acid was continued as 
permanent antiepileptic medication. Haloperidol and then clonazepam were administered to reduce 
dystonia, but the patient stopped these medications. Amitriptyline, nortriptyline and scopolamine 
were first prescribed to reduce saliva secretion, but local botulinum injections provided more 
effective relief. A biteplate helped protect his lips and gums. An Arabic language communicator 
was acquired. 
Due to the rarity of the disease and the variability of the clinical ChAc symptoms, diagnosis was 
challenging. The patient had clinical features consistent with the disease such as choreoathetosis, 
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orofacial dystonia and epileptic seizures. Our patient’s blood smear test was not considered 
diagnostic although routine blood smear tests have been shown to be less sensitive than the method 
by Storch et al which was not used here [9]. ChAc was finally diagnosed by genetic testing. 
Although we were unable to confirm that the two VPS13A gene mutations were biallelic as no 
family members were available for genetic testing, it is highly likely the patient is a compound 
heterozygote because of his clinical phenotype and his family history being consistent with 
autosomal recessive ChAc. 
In addition to the neurological symptoms, the patient had dermatological problems. The chronic 
eczema was, however, likely coincidental and the oral ulcerations were explained by involuntary 
repetitive biting. 
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HIGHLIGHTS 
 Chorea-acanthocytosis (ChAc) is a rare autosomal recessive neurodegenerative disease 
 two novel heterozygous VPS13A gene mutations were identified in a ChAc patient 
 often insufficient routine blood smear tests were not diagnostic for acanthocytosis 
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